Literature DB >> 16415723

Aripiprazole as a dopamine partial agonist: positive and negative effects.

Ira D Glick, Vandana Duggal, Charles Hodulik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16415723     DOI： 10.1097/01.jcp.0000196417.44847.0b

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  4 in total

1.  Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide.

Authors:  François Montastruc; Rui Nie; Simone Loo; Soham Rej; Sophie Dell'Aniello; Joëlle Micallef; Samy Suissa; Christel Renoux
Journal:  JAMA Psychiatry       Date:  2019-04-01       Impact factor: 21.596

2.  Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study.

Authors:  Pierre-Michel Llorca; Philippe Nuss; Éric Fakra; Isabelle Alamome; Dominique Drapier; Wissam El Hage; Renaud Jardri; Stéphane Mouchabac; Marc Rabbani; Nicolas Simon; Marie-Noëlle Vacheron; Jean-Michel Azorin
Journal:  BMC Psychiatry       Date:  2022-05-28       Impact factor: 4.144

Review 3.  A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.

Authors:  Hiroyoshi Takeuchi; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-06-05       Impact factor: 4.530

4.  A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder.

Authors:  Leslie Citrome
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.